Skip to content
MedsAcross

Medicine

Lamictal ODT 200 mg orally disintegrating tablet

Lamotrigine · Oral · GlaxoSmithKline
Available on requestPrescription onlyUS FDA

Lamictal ODT 200 mg orally disintegrating tablet is a prescription medicine containing Lamotrigine for oral use, marketed by GlaxoSmithKline, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) in a…

Key facts

Active ingredient (INN)
Lamotrigine
Brand
Lamictal ODT
Strength
200 mg
Dosage form
Orally disintegrating tablet
Route
Oral
Packs
1 dose pack
Marketing authorisation holder
GlaxoSmithKline
Manufacturer
GlaxoSmithKline
Origin register
US FDA, United States
Storage
Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) in a dry place. 100-mg, peach, scored, shield-shaped tablets debossed with “LAMICTAL” and “100”, bottles of 100 (NDC 0173-0642-55). 150-mg, cream, scored, shield-shaped tablets debossed with “LAMICTAL” and “150”, bottles of 60 (NDC 0173-0643-60). 200-mg, blue, scored, shield-shaped tablets debossed with “LAMICTAL” and…
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
N03AX09 Lamotrigine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
5 June 2009
Identifiers
RxCUI 103968, 105018, 105019 +7DailyMed set ID d7e3572d-56fe-4727-2bb4-013ccca22678NDC 0173-0777Application NDA022251

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 dose pack in 1 carton / 30 tablet, orally disintegrating in 1 dose pack0173-0777-02GlaxoSmithKline5 June 2009

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 27 December 1994Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Lamotrigine 200 mg orally disintegrating tablet.

Compare 1

Other strengths and forms of Lamotrigine

Clinical summary

Lamotrigine is an anti-epileptic agent indicated for epilepsy—adjunctive therapy in patients aged 2 years and older, among other approved uses. It is available as tablets, extended-release tablets and orally disintegrating tablets. MedsAcross supplies Lamotrigine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Lamotrigine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Lamictal ODT 200 mg orally disintegrating tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.